Form 4: Enliven Therapeutics CEO Samuel Kintz Executes Stock Sales Under 10b5-1 Plan

Enliven Therapeutics CEO Samuel Kintz sold shares of common stock on October 4 and October 7, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Samuel Kintz, the President and CEO of Enliven Therapeutics, sold shares of the company's common stock.
• The sales occurred on October 4 and October 7, 2024.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 26, 2023.
• On October 4, 12,206 shares were sold at a weighted average price of $27.5104.
• On October 7, 2,730 shares were sold at a price of $27.5.
• Following these transactions, Kintz directly owns 1,033,793 shares indirectly through The Kintz & Egan Trust Dated March 30, 2019, for which he serves as trustee.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to stock sales by an executive. It doesn't inherently indicate positive or negative sentiment, as it's a routine disclosure.

Industry Context

Insider selling is a common occurrence, especially when executives have pre-arranged trading plans like Rule 10b5-1. It's important to consider the context of these sales, such as the executive's overall holdings and the company's performance.

Stakeholder Impact

• Shareholders may react to the news of insider selling, although the existence of a 10b5-1 plan mitigates potential negative interpretations.

Key Dates